News Merck and Pfizer’s immunotherapy combination gains Breakthro... Merck and Pfizer have received a major boost to their immune-oncology alliance with a second FDA Breakthrough Therapy Designation for Bavencio, this time in combination with Pfizer’s Inlyta
Partner Content Partner Content CAR:T - Has biology outpaced the ability to deliver? Experts comment on manufacturing of CAR-T
Events Partner Content CAR-T Congress USA | 20 - 22 March 2018 | Boston Targeting | Commercialization | Scalability
Events Partner Content Combined CAR-T Congress Europe | 30 - 31 Jan 2018 Hear more about how to maximize CAR-T cell therapy
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
